226 related articles for article (PubMed ID: 14551895)
1. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
Moorthy VS; Pinder M; Reece WH; Watkins K; Atabani S; Hannan C; Bojang K; McAdam KP; Schneider J; Gilbert S; Hill AV
J Infect Dis; 2003 Oct; 188(8):1239-44. PubMed ID: 14551895
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.
Moorthy VS; Imoukhuede EB; Keating S; Pinder M; Webster D; Skinner MA; Gilbert SC; Walraven G; Hill AV
J Infect Dis; 2004 Jun; 189(12):2213-9. PubMed ID: 15181568
[TBL] [Abstract][Full Text] [Related]
3. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
McConkey SJ; Reece WH; Moorthy VS; Webster D; Dunachie S; Butcher G; Vuola JM; Blanchard TJ; Gothard P; Watkins K; Hannan CM; Everaere S; Brown K; Kester KE; Cummings J; Williams J; Heppner DG; Pathan A; Flanagan K; Arulanantham N; Roberts MT; Roy M; Smith GL; Schneider J; Peto T; Sinden RE; Gilbert SC; Hill AV
Nat Med; 2003 Jun; 9(6):729-35. PubMed ID: 12766765
[TBL] [Abstract][Full Text] [Related]
4. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.
Prieur E; Gilbert SC; Schneider J; Moore AC; Sheu EG; Goonetilleke N; Robson KJ; Hill AV
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):290-5. PubMed ID: 14694197
[TBL] [Abstract][Full Text] [Related]
5. Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
Mensah VA; Gueye A; Ndiaye M; Edwards NJ; Wright D; Anagnostou NA; Syll M; Ndaw A; Abiola A; Bliss C; Gomis JF; Petersen I; Ogwang C; Dieye T; Viebig NK; Lawrie AM; Roberts R; Nicosia A; Faye B; Gaye O; Leroy O; Imoukhuede EB; Ewer KJ; Bejon P; Hill AV; Cisse B;
PLoS One; 2016; 11(12):e0167951. PubMed ID: 27978537
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
Bejon P; Peshu N; Gilbert SC; Lowe BS; Molyneux CS; Forsdyke J; Lang T; Hill AV; Marsh K
Clin Infect Dis; 2006 Apr; 42(8):1102-10. PubMed ID: 16575727
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.
Bejon P; Mwacharo J; Kai OK; Todryk S; Keating S; Lang T; Gilbert SC; Peshu N; Marsh K; Hill AV
Vaccine; 2006 May; 24(22):4709-15. PubMed ID: 16621181
[TBL] [Abstract][Full Text] [Related]
8. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
Moorthy VS; Imoukhuede EB; Milligan P; Bojang K; Keating S; Kaye P; Pinder M; Gilbert SC; Walraven G; Greenwood BM; Hill AS
PLoS Med; 2004 Nov; 1(2):e33. PubMed ID: 15526058
[TBL] [Abstract][Full Text] [Related]
9. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.
Dunachie SJ; Walther M; Epstein JE; Keating S; Berthoud T; Andrews L; Andersen RF; Bejon P; Goonetilleke N; Poulton I; Webster DP; Butcher G; Watkins K; Sinden RE; Levine GL; Richie TL; Schneider J; Kaslow D; Gilbert SC; Carucci DJ; Hill AV
Infect Immun; 2006 Oct; 74(10):5933-42. PubMed ID: 16988273
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
Ogwang C; Afolabi M; Kimani D; Jagne YJ; Sheehy SH; Bliss CM; Duncan CJ; Collins KA; Garcia Knight MA; Kimani E; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Spencer AJ; Soipei P; Mueller J; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Gantlett K; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Urban BC; Flanagan KL; Ewer KJ; Chilengi R; Hill AV; Bojang K
PLoS One; 2013; 8(3):e57726. PubMed ID: 23526949
[TBL] [Abstract][Full Text] [Related]
11. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
Imoukhuede EB; Berthoud T; Milligan P; Bojang K; Ismaili J; Keating S; Nwakanma D; Keita S; Njie F; Sowe M; Todryk S; Laidlaw SM; Skinner MA; Lang T; Gilbert S; Greenwood BM; Hill AV
Vaccine; 2006 Oct; 24(42-43):6526-33. PubMed ID: 16842888
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.
Epstein JE; Charoenvit Y; Kester KE; Wang R; Newcomer R; Fitzpatrick S; Richie TL; Tornieporth N; Heppner DG; Ockenhouse C; Majam V; Holland C; Abot E; Ganeshan H; Berzins M; Jones T; Freydberg CN; Ng J; Norman J; Carucci DJ; Cohen J; Hoffman SL
Vaccine; 2004 Apr; 22(13-14):1592-603. PubMed ID: 15068840
[TBL] [Abstract][Full Text] [Related]
14. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
Webster DP; Dunachie S; McConkey S; Poulton I; Moore AC; Walther M; Laidlaw SM; Peto T; Skinner MA; Gilbert SC; Hill AV
Vaccine; 2006 Apr; 24(15):3026-34. PubMed ID: 16488059
[TBL] [Abstract][Full Text] [Related]
15. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees.
Schneider J; Langermans JA; Gilbert SC; Blanchard TJ; Twigg S; Naitza S; Hannan CM; Aidoo M; Crisanti A; Robson KJ; Smith GL; Hill AV; Thomas AW
Vaccine; 2001 Sep; 19(32):4595-602. PubMed ID: 11535306
[TBL] [Abstract][Full Text] [Related]
16. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
[TBL] [Abstract][Full Text] [Related]
17. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.
Rampling T; Ewer KJ; Bowyer G; Bliss CM; Edwards NJ; Wright D; Payne RO; Venkatraman N; de Barra E; Snudden CM; Poulton ID; de Graaf H; Sukhtankar P; Roberts R; Ivinson K; Weltzin R; Rajkumar BY; Wille-Reece U; Lee CK; Ockenhouse CF; Sinden RE; Gerry S; Lawrie AM; Vekemans J; Morelle D; Lievens M; Ballou RW; Cooke GS; Faust SN; Gilbert S; Hill AV
J Infect Dis; 2016 Sep; 214(5):772-81. PubMed ID: 27307573
[TBL] [Abstract][Full Text] [Related]
18. Progress in DNA-based heterologous prime-boost immunization strategies for malaria.
Moore AC; Hill AV
Immunol Rev; 2004 Jun; 199():126-43. PubMed ID: 15233731
[TBL] [Abstract][Full Text] [Related]
19. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
O'Hara GA; Duncan CJ; Ewer KJ; Collins KA; Elias SC; Halstead FD; Goodman AL; Edwards NJ; Reyes-Sandoval A; Bird P; Rowland R; Sheehy SH; Poulton ID; Hutchings C; Todryk S; Andrews L; Folgori A; Berrie E; Moyle S; Nicosia A; Colloca S; Cortese R; Siani L; Lawrie AM; Gilbert SC; Hill AV
J Infect Dis; 2012 Mar; 205(5):772-81. PubMed ID: 22275401
[TBL] [Abstract][Full Text] [Related]
20. Can malaria DNA vaccines on their own be as immunogenic and protective as prime-boost approaches to immunization?
Hoffman SL; Doolan DL
Dev Biol (Basel); 2000; 104():121-32. PubMed ID: 11713810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]